Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280496847> ?p ?o ?g. }
- W4280496847 abstract "Abstract Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe 2+ efflux efficiency via the β-catenin/TCF4-SLC7A11/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer." @default.
- W4280496847 created "2022-05-22" @default.
- W4280496847 creator A5000675789 @default.
- W4280496847 creator A5010647539 @default.
- W4280496847 creator A5012884973 @default.
- W4280496847 creator A5014307249 @default.
- W4280496847 creator A5021504410 @default.
- W4280496847 creator A5026279705 @default.
- W4280496847 creator A5038895527 @default.
- W4280496847 creator A5039735091 @default.
- W4280496847 creator A5043059315 @default.
- W4280496847 creator A5044867727 @default.
- W4280496847 creator A5048093999 @default.
- W4280496847 creator A5049156370 @default.
- W4280496847 creator A5056709159 @default.
- W4280496847 creator A5057676647 @default.
- W4280496847 creator A5079649997 @default.
- W4280496847 creator A5082811889 @default.
- W4280496847 date "2022-05-13" @default.
- W4280496847 modified "2023-10-14" @default.
- W4280496847 title "N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer" @default.
- W4280496847 cites W1960850967 @default.
- W4280496847 cites W1966937303 @default.
- W4280496847 cites W1973116775 @default.
- W4280496847 cites W1975617209 @default.
- W4280496847 cites W1982873976 @default.
- W4280496847 cites W1983886177 @default.
- W4280496847 cites W1997183854 @default.
- W4280496847 cites W2001447115 @default.
- W4280496847 cites W2006070721 @default.
- W4280496847 cites W2020372547 @default.
- W4280496847 cites W2040935952 @default.
- W4280496847 cites W2059411043 @default.
- W4280496847 cites W2068326740 @default.
- W4280496847 cites W2093447167 @default.
- W4280496847 cites W2095156669 @default.
- W4280496847 cites W2100122648 @default.
- W4280496847 cites W2108459871 @default.
- W4280496847 cites W2132619562 @default.
- W4280496847 cites W2137673157 @default.
- W4280496847 cites W2140354367 @default.
- W4280496847 cites W2141393790 @default.
- W4280496847 cites W2146384083 @default.
- W4280496847 cites W2149773268 @default.
- W4280496847 cites W2154834163 @default.
- W4280496847 cites W2159967578 @default.
- W4280496847 cites W2163531544 @default.
- W4280496847 cites W2172265576 @default.
- W4280496847 cites W2239511084 @default.
- W4280496847 cites W2305753128 @default.
- W4280496847 cites W2318605753 @default.
- W4280496847 cites W2410078130 @default.
- W4280496847 cites W2488521558 @default.
- W4280496847 cites W2506902454 @default.
- W4280496847 cites W2521763776 @default.
- W4280496847 cites W2574695762 @default.
- W4280496847 cites W2588881638 @default.
- W4280496847 cites W2595713273 @default.
- W4280496847 cites W2604646569 @default.
- W4280496847 cites W2624590002 @default.
- W4280496847 cites W2741222274 @default.
- W4280496847 cites W2773981699 @default.
- W4280496847 cites W2787209010 @default.
- W4280496847 cites W2789073946 @default.
- W4280496847 cites W2799444748 @default.
- W4280496847 cites W2883208697 @default.
- W4280496847 cites W2901265038 @default.
- W4280496847 cites W2936895904 @default.
- W4280496847 cites W2941542116 @default.
- W4280496847 cites W2945161487 @default.
- W4280496847 cites W2949159574 @default.
- W4280496847 cites W2964040556 @default.
- W4280496847 cites W2968612009 @default.
- W4280496847 cites W2968971583 @default.
- W4280496847 cites W2971050114 @default.
- W4280496847 cites W2979291688 @default.
- W4280496847 cites W2981669117 @default.
- W4280496847 cites W2982916409 @default.
- W4280496847 cites W2990527211 @default.
- W4280496847 cites W2995808512 @default.
- W4280496847 cites W2998463707 @default.
- W4280496847 cites W3000124759 @default.
- W4280496847 cites W3001540396 @default.
- W4280496847 cites W3004667471 @default.
- W4280496847 cites W3010469101 @default.
- W4280496847 cites W3010679447 @default.
- W4280496847 cites W3012380787 @default.
- W4280496847 cites W3037464909 @default.
- W4280496847 cites W3037940748 @default.
- W4280496847 cites W3084074691 @default.
- W4280496847 cites W3084918145 @default.
- W4280496847 cites W3092854160 @default.
- W4280496847 cites W3104822654 @default.
- W4280496847 cites W3123971507 @default.
- W4280496847 cites W3126817559 @default.
- W4280496847 cites W3128646645 @default.
- W4280496847 cites W3134087839 @default.
- W4280496847 cites W3157399439 @default.
- W4280496847 cites W3163368161 @default.
- W4280496847 cites W3198511950 @default.